Leerink Partners analyst Jonathan Chang has reiterated their bullish stance on IMCR stock, giving a Buy rating on March 11.
Jonathan Chang has given his Buy rating due to a combination of factors including Immunocore Holdings’ promising development strategy and strong financial position. Despite the mixed initial data from the multiple ascending dose study of IMC-M113V in HIV, the program is still viewed as a potential upside to valuation. The study demonstrated consistent safety and tolerability, which is a positive indicator for future developments.
Additionally, Immunocore’s experienced management team and proven history of success contribute to the confidence in their ability to execute the development of their TCR bispecific programs. Although the antiviral activity showed only modest results, the company is actively exploring alternative measurements and further data from higher-dose cohorts is anticipated. These elements combined support the Buy rating for Immunocore Holdings’ stock.
In another report released on March 11, Barclays also maintained a Buy rating on the stock with a $66.00 price target.